BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Deals

  4 Possible Biotech Takeover Targets for 2018

  This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.

  December 12, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  Why This Massachusetts Synthetic Bio Startup Could be the Next Biotech Unicorn

  In investment jargon, a “unicorn” has at least two meanings.

  December 12, 2017

   · 

  3 min read

   · 

  Mark Terry
• Drug Development

  First Time Ever: Scientists Fix Huntington’s Protein Defect With Ionis Pharma Drug

  The success has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million.

  December 12, 2017

   · 

  1 min read
• 

  Business

  What You Need to Know About Prelude Fertility

  Prelude Fertility was founded in late 2016 by successful startup entrepreneur Martin Varsavsky with a $200M investment.

  December 12, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  265 Employees Affected as San Diego’s Dart NeuroScience Decides to Close Its Doors

  Dart will close its doors on Feb. 9 due to poor progress on its therapeutic goals and little return on hundreds of millions of dollars in R&D.

  December 12, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  AbbVie, Genentech’s Venclexta Plus Rituxan Crushes Chemo in Rituxan CLL Study

  At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.

  December 12, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  J&J, Sanofi Top Bioethics International Transparency Report

  Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck.

  December 12, 2017

   · 

  4 min read

   · 

  Alex Keown
• 

  Pharm Country

  Why 2018 Could be Cara Therapeutics’ Year

  Most investors would be excited if one of the stocks they owned achieved a 45% gain in less than a year.

  December 12, 2017

   · 

  1 min read
• 

  Drug Development

  ASH Burns Bright With Excitement

  A look at some of the exciting data clinicians and investors got to feast on from ASH.

  December 12, 2017

   · 

  1 min read
• 

  Business

  Gilead Doubles Down on CAR-T

  Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.

  December 12, 2017

   · 

  1 min read